Skip to main content
Fig. 12 | Journal of Experimental & Clinical Cancer Research

Fig. 12

From: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Fig. 12

Effect of CHK1 inhibitors in 3D-models of breast cancer. Images (A, B) and quantitation (A’, B’) of tumor spheroids surface area (A, A’) and alginate-based cultures (B, B’) generated in MCF-7 and Y537S cells, treated at time 0 with CHK1 inhibitors (i.e., AZD7762, AZD—1 μM; prexasertib, Prexa—1 μM; MK8776—MK 5 μM) or left untreated (CTR), for 7 days. The number of replicates is given as solid dots in the graphs. Significant differences with respect to the CTR sample were determined by unpaired two-tailed Student’s t-test: **** p-value < 0.0001; *** p-value < 0.001. Scale bars equal to 200 µm for panel A and 50.0 mm for panel B

Back to article page